Leader of Global
HLB navigates the way to the future by developing
First-in-class drugs with continuous innovation and challenges.
About the Progress of the Global Ri...
∙ On February 26, HLB signed a binding term sheet with Adenchen Laboratories, the original developer of Rivoceranib, t...
Apealea completes Pre-NDA meeting
On April 30th, Oasmia pharmaceutical AB (Oasmia) held FDA's ovarian cancer pre-NDA meeting for Apealea, which Elevar Th...
Elevar Therapeutics to Participate...
Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company...
FDA Approval Sought for Frontline C...
A new drug application (NDA) has been submitted to the FDA, seeking approval of rivoceranib in combination with camreliz...
Low-dose apatinib monothe...
AbstractThe therapeutic regimen for small cell lung cancer (SCLC)...
Tumor Angiogenesis and An...
AbstractAngiogenesis is the process through which novel blood ves...